CanSino Biologics and Precision NanoSystems Announce Collaboration to Co-Develop a COVID-19 RNA Vaccine

CanSinoBIO will license in Precision NanoSystems' proprietary RNA vaccine platform technology

Precision NanoSystems will lead RNA vaccine formulation development

CanSinoBIO will lead COVID-19 antigen design,pre-clinical testing and clinical trials

TIANJIN,China and VANCOUVER,British Columbia,May 20,2020 -- CanSino Biologics Inc. (CanSinoBIO,HK6185) and Precision NanoSystems (PNI) today announced a co-development agreement of a mRNA lipid nanoparticle (mRNA-LNP) vaccine against COVID-19. The parties will leverage PNI's proprietary RNA vaccine platform,comprising of lipid nanoparticle delivery system and the NanoAssemblr® manufacturing technology,to rapidly advance a COVID-19 mRNA-LNP vaccine candidate towards human clinical testing and pursuant to regulatory approvals,commercialization in different regions. PNI will be responsible for development of the mRNA-LNP vaccine and CanSinoBIO will be responsible for pre-clinical testing,human clinical trials,regulatory approval and commercialization. CanSinoBIO has rights to commercialize the vaccine product in Asia (except Japan) with PNI retaining rights for rest of the world. The agreement includes undisclosed payments and royalties.

The NanoAssemblr(R) Ignite(TM) with NxGen Technology is a scalable,easy to use,and reproducible system that enables the creation of transformative medicines.

CanSinoBIO is at the forefront of COVID-19 vaccine development efforts with their Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) candidate (the Ad5-nCoV ) currently in phase II clinical trial in China. CanSinoBIO recently announced a collaboration with the National Research Council of Canada to initiate clinical testing of the Ad5-nCoV vaccine candidate in Canada. In parallel to clinical development of Ad5-nCoV,CanSinoBIO wants to join efforts with PNI to develop and commercialize a mRNA-LNP based vaccine. CanSinoBIO's co-founder,chairman and CEO Dr. Xuefeng Yu said,"Our team has been dedicated to developing safe and effective vaccines to fight against the COVID-19 pandemic.Since RNA vaccines are a disruptive technology as they do not require cell culture,utilize synthetic delivery and have a smaller manufacturing footprint,our partnership with PNI to advance a mRNA-LNP vaccine candidate will not only help accelerate the process,but will also potentiallyrevolutionize the vaccine industry."

PNI is a global leader in technologies and solutions for the development and manufacture of nanomedicines. With over 400 NanoAssemblr® systems placed,PNI supports its customers' drug development and manufacturing efforts in the areas of oncology,infectious diseases,and rare diseases. To offer a complete solution for drug developers,PNI has developed a library of lipid formulations for nucleic acid delivery. Dr. Andrew Geall,CSO at PNI and a scientific leader in the field of non-viral delivery of mRNA vaccines said,"PNI has developed lipid formulations that are specifically designed for vaccine applications and we look forward to working with CanSinoBIO to bring the vaccine to patients." PNI's NanoAssemblr® GMP System and manufacturing process,now transferred to several customers,plays a crucial role in scalable,high throughput,reproducible centralized or regional manufacturing of nanomedicines. Dr. James Taylor,co-founder and CEO of PNI said,"We are very excited to partner with CanSinoBIO,an innovative biopharmaceutical company leading the way for COVID-19 vaccine development. We strongly believe PNI's NxGen microfluidic technology and our expertise will enable the rapid development and manufacturing of an effective mRNA-LNP vaccine for COVID-19,and provides the foundation for future pandemic preparedness.

About CanSinoBIO

Incorporated in 2009,CanSinoBIO (6185.HK) commits to research,production and commercialization of innovative vaccines for China and global public health security. It possesses four integrated platform technologies including adenovirus-based vectors,conjugation,protein design and recombination and formulation. As of today,it has established a robust pipeline of 16 vaccines covering 13 diseases,including a globally innovative Ebola virus vaccine approved for marketing in 2017 as well as the investigational Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector).

About Precision NanoSystems Inc.

Precision NanoSystems Inc. (PNI) proprietary NanoAssemblr Platform enables the rapid,reproducible,and scalable manufacture of next generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to cells and tissues in the body. PNI provides instruments,reagents and services to life sciences researchers,including pharmaceutical companies,and builds strategic collaborations to revolutionize healthcare through nanotechnology. For more information visithttp://www.precisionnanosystems.com.

Contact: Jane Alleva,Global Marketing Director,Precision NanoSystems,mobile 1 778 877 5473,jalleva@precision-nano.com; CanSino Biologics Inc.,+86 22 58213600,info@cansinotech.com

Photo - http://cusmail.com/res/2023/07-23/21/f85a2748da419c7e010f3445eca823fc.jpg